The reviewed studies suggest that individual variability in the rate of nicotine metabolism influences smoking behavior and response to smoking cessation treatments. Given the large number of CYP2A6 alleles, as well as the influence of environmental factors on nicotine metabolism, a phenotypic biomarker of CYP2A6 activity (3HC/cotinine) appears to be a more robust predictor of cessation than genotype.
